Cargando…

Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines

Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Albutti, Aqel, Longet, Stephanie, McEntee, Craig P., Quinn, Shauna, Liddicoat, Alex, Rîmniceanu, Cristiana, Lycke, Nils, Lynch, Lydia, Cardell, Susanna, Lavelle, Ed C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230052/
https://www.ncbi.nlm.nih.gov/pubmed/34201310
http://dx.doi.org/10.3390/vaccines9060619
_version_ 1783713116179136512
author Albutti, Aqel
Longet, Stephanie
McEntee, Craig P.
Quinn, Shauna
Liddicoat, Alex
Rîmniceanu, Cristiana
Lycke, Nils
Lynch, Lydia
Cardell, Susanna
Lavelle, Ed C.
author_facet Albutti, Aqel
Longet, Stephanie
McEntee, Craig P.
Quinn, Shauna
Liddicoat, Alex
Rîmniceanu, Cristiana
Lycke, Nils
Lynch, Lydia
Cardell, Susanna
Lavelle, Ed C.
author_sort Albutti, Aqel
collection PubMed
description Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or immunological tolerance. The effectiveness of oral vaccination can be improved by co-administering adjuvants. However, a major challenge is the absence of potent and safe oral adjuvants for clinical application. Here, the Type II NKT cell activator sulfatide is shown for the first time to be an effective oral adjuvant for Vibrio cholerae vaccine antigens in a mouse model. Specifically, administration of sulfatide with the oral cholera vaccine Dukoral(®) resulted in enhancement of intestinal antigen-specific IgA in addition to Th1 and Th17 immune responses. In summary, sulfatide is a promising adjuvant for inclusion in an oral cholera vaccine and our data further support the potential of adjuvants targeting NKT cells in new vaccine strategies.
format Online
Article
Text
id pubmed-8230052
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82300522021-06-26 Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines Albutti, Aqel Longet, Stephanie McEntee, Craig P. Quinn, Shauna Liddicoat, Alex Rîmniceanu, Cristiana Lycke, Nils Lynch, Lydia Cardell, Susanna Lavelle, Ed C. Vaccines (Basel) Article Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or immunological tolerance. The effectiveness of oral vaccination can be improved by co-administering adjuvants. However, a major challenge is the absence of potent and safe oral adjuvants for clinical application. Here, the Type II NKT cell activator sulfatide is shown for the first time to be an effective oral adjuvant for Vibrio cholerae vaccine antigens in a mouse model. Specifically, administration of sulfatide with the oral cholera vaccine Dukoral(®) resulted in enhancement of intestinal antigen-specific IgA in addition to Th1 and Th17 immune responses. In summary, sulfatide is a promising adjuvant for inclusion in an oral cholera vaccine and our data further support the potential of adjuvants targeting NKT cells in new vaccine strategies. MDPI 2021-06-08 /pmc/articles/PMC8230052/ /pubmed/34201310 http://dx.doi.org/10.3390/vaccines9060619 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Albutti, Aqel
Longet, Stephanie
McEntee, Craig P.
Quinn, Shauna
Liddicoat, Alex
Rîmniceanu, Cristiana
Lycke, Nils
Lynch, Lydia
Cardell, Susanna
Lavelle, Ed C.
Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
title Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
title_full Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
title_fullStr Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
title_full_unstemmed Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
title_short Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
title_sort type ii nkt cell agonist, sulfatide, is an effective adjuvant for oral heat-killed cholera vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230052/
https://www.ncbi.nlm.nih.gov/pubmed/34201310
http://dx.doi.org/10.3390/vaccines9060619
work_keys_str_mv AT albuttiaqel typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT longetstephanie typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT mcenteecraigp typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT quinnshauna typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT liddicoatalex typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT rimniceanucristiana typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT lyckenils typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT lynchlydia typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT cardellsusanna typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines
AT lavelleedc typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines